Christopher Sullivan
2021
In 2021, Christopher Sullivan earned a total compensation of $627.6K as Chief Financial Officer and principal financial officer at Avalo Therapeutics.
Compensation breakdown
| Non-Equity Incentive Plan | $85,860 |
|---|---|
| Option Awards | $241,782 |
| Salary | $300,000 |
| Total | $627,642 |
Sullivan received $300K in salary, accounting for 48% of the total pay in 2021.
Sullivan also received $85.9K in non-equity incentive plan and $241.8K in option awards.
Rankings
In 2021, Christopher Sullivan's compensation ranked 10,197th out of 12,412 executives tracked by ExecPay. In other words, Sullivan earned more than 17.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,197 out of 12,412 | 18th |
Division Manufacturing | 4,508 out of 5,498 | 18th |
Major group Chemicals And Allied Products | 2,015 out of 2,374 | 15th |
Industry group Drugs | 1,786 out of 2,095 | 15th |
Industry Pharmaceutical Preparations | 1,326 out of 1,542 | 14th |
Source: SEC filing on October 19, 2023.
Sullivan's colleagues
We found four more compensation records of executives who worked with Christopher Sullivan at Avalo Therapeutics in 2021.